Stock events for Arrivent BioPharma, Inc. (AVBP)
In the past six months, ArriVent BioPharma's stock price has been impacted by analyst coverage and price target adjustments, clinical trial progress, financial reporting, other corporate news, and stock performance. Several analysts reaffirmed or initiated coverage with "Buy" or "Outperform" ratings and adjusted price targets. The company announced the first patient dosed in the global pivotal Phase 3 ALPACCA trial and presented final Phase 1b results for firmonertinib. ArriVent BioPharma reported its full-year and third-quarter 2025 financial results, with the company reporting ($0.78) earnings per share (EPS) for the quarter ending March 9, 2026, beating the consensus estimate of ($0.87). Brent S. Rice was appointed as Chief Commercial Officer. The stock's 52-week high was $27.22 and its 52-week low was $15.47, with a share price of $22.97 as of February 27, 2026.
Demand Seasonality affecting Arrivent BioPharma, Inc.’s stock price
As a clinical-stage biopharmaceutical company, ArriVent BioPharma, Inc. is primarily focused on research, development, and clinical trials of its product candidates. The company does not yet have commercialized products generating revenue, so there is no discernible demand seasonality for its products or services at this stage of its business.
Overview of Arrivent BioPharma, Inc.’s business
ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing medicines for difficult-to-treat cancers. The company operates in the Healthcare sector, specifically in the Biotechnology and Pharmaceuticals industries. ArriVent BioPharma's business model is centered on investment in research and development, late-stage clinical trials, and pipeline expansion. The company's major product candidates include firmonertinib, ARR-217, ARR-002, ARR-421 and ARR-173.
AVBP’s Geographic footprint
ArriVent BioPharma, Inc. is headquartered in Newtown Square, Pennsylvania, United States. The company emphasizes accelerating the global development of innovative medicines, with its lead candidate firmonertinib being studied in a global pivotal Phase 3 trial. Its collaboration agreements, such as the one for ARR-217, also highlight a global reach with specific regional commercialization rights.
AVBP Corporate Image Assessment
ArriVent BioPharma's brand reputation appears to be largely positive, driven by favorable analyst sentiment and progress in its clinical pipeline. The company has received numerous "Buy" and "Outperform" ratings from brokerage firms, with an average brokerage recommendation indicating "Outperform" status. Analysts have also set an average target price suggesting a significant upside potential for the stock. The positive sentiment is reinforced by an earnings per share beat in the most recent quarter. There have been no specific events reported that have negatively impacted ArriVent BioPharma's reputation in the past year.
Ownership
ArriVent BioPharma, Inc. has significant institutional ownership, with 147 institutional owners holding a total of 37,567,486 shares. Institutional shareholders own 97.15% of the company, while individual insiders hold 24.11%, and retail investors hold 0.00%. Major institutional and individual owners include Infinitum Asset Management, Llc, Suvretta Capital Management, Llc, Hillhouse Capital Advisors, Ltd., Fmr Llc, Orbimed Advisors Llc, BlackRock, Inc., Octagon Capital Advisors LP, Vanguard Group Inc, Sofinnova Investments, Inc., General Catalyst Group Management, Llc, HBM Partners Ltd., and Eli Lilly Investment Consulting (Shanghai) Co., Ltd.
